BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/11/2025 1:10:34 PM | Browse: 38 | Download: 0
Category |
Health Care Sciences & Services |
Manuscript Type |
Review |
Article Title |
Obinutuzumab in kidney transplantation: Past, present, and future
|
Manuscript Source |
Invited Manuscript |
All Author List |
Evaldo Favi and Marika Morabito |
Funding Agency and Grant Number |
|
Corresponding Author |
Evaldo Favi, MD, PhD, Department of General Surgery and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza No. 28, Milan 20122, Lombardy, Italy. evaldofavi@gmail.com |
Key Words |
Obinutuzumab; Rituximab; Kidney transplantation; Desensitization; Antibody-mediated rejection; Glomerulopathies; Recurrence; Review |
Core Tip |
Antibody-mediated rejection and recurrent primary renal diseases remain major causes of kidney transplant loss. Obinutuzumab (OBI) is a type 2 anti-CD20 monoclonal antibody with enhanced peripheral and central B-cell depletion capacities compared to type 1 anti-CD20 monoclonal antibodies. Compared to other B-cell-targeted agents, OBI-induced B-cell depletion is marginally affected by complement function, primarily operating through antibody-dependent cell cytotoxicity, antibody-dependent cell phagocytosis, and direct cell death. These characteristics suggest that OBI might represent a game-changer in the management of highly sensitized transplant candidates, humoral rejection, and relapsing renal diseases. This review summarizes the current knowledge on OBI use in kidney transplantation. |
Citation |
Favi E, Morabito M. Obinutuzumab in kidney transplantation: Past, present, and future. World J Transplant 2025; In press |
 |
Received |
|
2025-04-27 05:39 |
 |
Peer-Review Started |
|
2025-04-27 05:39 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-05-12 04:19 |
 |
Revised |
|
2025-05-26 08:02 |
 |
Second Decision |
|
2025-08-11 02:52 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-08-11 13:10 |
 |
Articles in Press |
|
2025-08-11 13:10 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
ISSN |
2220-3230 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345